Predictors of Unfavorable Treatment Outcome in Patients with Multidrug-Resistant Tuberculosis: A Prospective Study
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 3, Pages 4662-4668
AbstractBackground: World health organization suggest that final multidrug resistant tuberculosis treatment outcome is the most important direct measurement of the effectiveness of the multidrug resistant tuberculosis treatment control Programme, thus WHO conditionally guideline recommended standardised shorter9-12 month regimens for multidrug resistant TB treatment. Thus, for better understanding of the risk factor for unfavorable outcomes this study has conducted.
Material and Methods : A Prospective study including patients with sputum CBNAAT diagnosed as DR TB, who has undergone treatment with shorter MDR TB regimen as in patient & out patient in the District Nodal TB centre, department of Pulmonary Medicine, Government Medical College, Siddipet, during the period of one and half year. After getting ethical approval from, institutional committee.
Results : In the study we have enrolled 100 patients, out of 52% were males and 48% were females, mean age of all the patients were 41.86 ± 16.56 years also mean body mass index of the patient was 19.23 ± 6.45. Out of all 23% of the patients unfavorable outcomes were observed in that, 10 patients died for 9 patients treatment regimen changed, we lost follow up for 3 patients and for only one patient treatment was failed.
Conclusion : We can conclude from above results and observation that, though the success rate of our study was nearer to WHO global rate to stop TB. To achive this strategies for early diagnosis and management of MDR-TB should improve treatment outcomes to reduce death and stop further transmission.
- Article View: 48
- PDF Download: 69